These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ý
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
¨
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
|
Leidos Holdings, Inc.
|
|
|
(Exact name of registrant as specified in its charter)
|
|
|
|
Delaware
|
|
20-3562868
|
|
(State or other jurisdiction of incorporation or organization)
|
|
(I.R.S. Employer Identification No.)
|
|
|
|
|
|
11951 Freedom Drive, Reston, Virginia
|
|
20190
|
|
(Address of principal executive office)
|
|
(Zip Code)
|
|
|
|
|
|
(571) 526-6000
|
||
|
(Registrant's telephone number, including area code)
|
||
|
|
Large accelerated filer
|
x
|
|
|
|
|
Accelerated filer
|
¨
|
|
|
|
Non-accelerated filer
|
¨
|
(Do not check if a smaller reporting company)
|
|
Smaller reporting company
|
¨
|
|
||
|
|
|
|
|
|
|
|
Emerging growth company
|
¨
|
|
|
|
|
Page
|
|
Part I
|
|
|
|
|
|
|
|
Item 1.
|
||
|
|
|
|
|
Item 2.
|
||
|
|
|
|
|
Item 3.
|
||
|
|
|
|
|
Item 4.
|
||
|
|
|
|
|
Part II
|
|
|
|
|
|
|
|
Item 1.
|
||
|
|
|
|
|
Item 1A.
|
||
|
|
|
|
|
Item 2.
|
||
|
|
|
|
|
Item 3.
|
||
|
|
|
|
|
Item 4.
|
||
|
|
|
|
|
Item 5.
|
||
|
|
|
|
|
Item 6.
|
||
|
|
|
|
|
|
||
|
|
|
March 31,
2017 |
|
December 30,
2016 |
||||
|
|
|
(in millions)
|
||||||
|
ASSETS
|
|
|
|
|
||||
|
Current assets:
|
|
|
|
|
||||
|
Cash and cash equivalents
|
|
$
|
206
|
|
|
$
|
376
|
|
|
Receivables, net
|
|
1,841
|
|
|
1,657
|
|
||
|
Inventory, prepaid expenses and other current assets
|
|
348
|
|
|
348
|
|
||
|
Total current assets
|
|
2,395
|
|
|
2,381
|
|
||
|
Property, plant and equipment, net
|
|
238
|
|
|
259
|
|
||
|
Intangible assets, net
|
|
1,520
|
|
|
1,589
|
|
||
|
Goodwill
|
|
4,619
|
|
|
4,622
|
|
||
|
Deferred tax assets
|
|
15
|
|
|
16
|
|
||
|
Other assets
|
|
353
|
|
|
265
|
|
||
|
|
|
$
|
9,140
|
|
|
$
|
9,132
|
|
|
LIABILITIES AND EQUITY
|
|
|
|
|
||||
|
Current liabilities:
|
|
|
|
|
||||
|
Accounts payable
|
|
$
|
592
|
|
|
$
|
591
|
|
|
Accrued liabilities
|
|
837
|
|
|
836
|
|
||
|
Accrued payroll and employee benefits
|
|
396
|
|
|
483
|
|
||
|
Dividends payable
|
|
21
|
|
|
23
|
|
||
|
Income taxes payable
|
|
53
|
|
|
21
|
|
||
|
Notes payable and long-term debt, current portion
|
|
84
|
|
|
62
|
|
||
|
Total current liabilities
|
|
1,983
|
|
|
2,016
|
|
||
|
Notes payable and long-term debt, net of current portion
|
|
3,188
|
|
|
3,225
|
|
||
|
Deferred tax liabilities
|
|
564
|
|
|
540
|
|
||
|
Other long-term liabilities
|
|
217
|
|
|
204
|
|
||
|
Stockholders’ equity:
|
|
|
|
|
||||
|
Common stock, $.0001 par value, 500 million shares authorized, 151 million and 150 million shares issued and outstanding at March 31, 2017 and December 30, 2016, respectively
|
|
—
|
|
|
—
|
|
||
|
Additional paid-in capital
|
|
3,323
|
|
|
3,316
|
|
||
|
Accumulated deficit
|
|
(154
|
)
|
|
(177
|
)
|
||
|
Accumulated other comprehensive income (loss)
|
|
8
|
|
|
(4
|
)
|
||
|
Total Leidos stockholders’ equity
|
|
3,177
|
|
|
3,135
|
|
||
|
Non-controlling interest
|
|
11
|
|
|
12
|
|
||
|
Total equity
|
|
3,188
|
|
|
3,147
|
|
||
|
|
|
$
|
9,140
|
|
|
$
|
9,132
|
|
|
|
|
Three Months Ended
|
||||||
|
|
|
March 31,
2017 |
|
April 1,
2016 |
||||
|
|
|
(in millions, except per share amounts)
|
||||||
|
Revenues
|
|
$
|
2,580
|
|
|
$
|
1,312
|
|
|
Cost of revenues
|
|
2,270
|
|
|
1,154
|
|
||
|
Selling, general and administrative expenses
|
|
144
|
|
|
60
|
|
||
|
Acquisition and integration costs
|
|
19
|
|
|
9
|
|
||
|
Restructuring expenses
|
|
13
|
|
|
—
|
|
||
|
Equity earnings of non-consolidated subsidiaries
|
|
(7
|
)
|
|
—
|
|
||
|
Operating income
|
|
141
|
|
|
89
|
|
||
|
Interest income
|
|
2
|
|
|
3
|
|
||
|
Interest expense
|
|
(38
|
)
|
|
(14
|
)
|
||
|
Other income, net
|
|
3
|
|
|
—
|
|
||
|
Income from continuing operations before income taxes
|
|
108
|
|
|
78
|
|
||
|
Income tax expense
|
|
(34
|
)
|
|
(25
|
)
|
||
|
Net income
|
|
74
|
|
|
53
|
|
||
|
Less: net income attributable to non-controlling interest, net of taxes
|
|
2
|
|
|
—
|
|
||
|
Net income attributable to Leidos common stockholders
|
|
$
|
72
|
|
|
$
|
53
|
|
|
Earnings per share:
|
|
|
|
|
||||
|
Basic
|
|
$
|
0.48
|
|
|
$
|
0.74
|
|
|
Diluted
|
|
0.47
|
|
|
0.72
|
|
||
|
|
|
|
|
|
||||
|
Cash dividends declared per share
|
|
$
|
0.32
|
|
|
$
|
0.32
|
|
|
|
|
Three Months Ended
|
||||||
|
|
|
March 31,
2017 |
|
April 1,
2016 |
||||
|
|
|
(in millions)
|
||||||
|
Net income
|
|
$
|
74
|
|
|
$
|
53
|
|
|
Other comprehensive income, net of taxes:
|
|
|
|
|
||||
|
Foreign currency translation adjustments
|
|
11
|
|
|
2
|
|
||
|
Unrecognized gain on derivative instruments
|
|
1
|
|
|
—
|
|
||
|
Total other comprehensive income, net of taxes
|
|
12
|
|
|
2
|
|
||
|
Comprehensive income
|
|
86
|
|
|
55
|
|
||
|
Less: comprehensive income attributable to non-controlling interest, net of taxes
|
|
2
|
|
|
—
|
|
||
|
Comprehensive income attributable to Leidos common stockholders
|
|
$
|
84
|
|
|
$
|
55
|
|
|
|
|
Three Months Ended
|
||||||
|
|
|
March 31,
2017 |
|
April 1,
2016 |
||||
|
|
|
(in millions)
|
||||||
|
Cash flows from operations:
|
|
|
|
|
||||
|
Net income
|
|
$
|
74
|
|
|
$
|
53
|
|
|
Adjustments to reconcile net income to net cash used in operations:
|
|
|
|
|
||||
|
Depreciation and amortization
|
|
82
|
|
|
8
|
|
||
|
Stock-based compensation
|
|
10
|
|
|
8
|
|
||
|
Other
|
|
2
|
|
|
2
|
|
||
|
Change in assets and liabilities, net of effects of acquisitions and dispositions:
|
|
|
|
|
||||
|
Receivables
|
|
(190
|
)
|
|
(48
|
)
|
||
|
Inventory, prepaid expenses and other current assets
|
|
6
|
|
|
(11
|
)
|
||
|
Accounts payable and accrued liabilities
|
|
(37
|
)
|
|
18
|
|
||
|
Accrued payroll and employee benefits
|
|
(86
|
)
|
|
(51
|
)
|
||
|
Deferred income taxes and income taxes receivable/payable
|
|
31
|
|
|
9
|
|
||
|
Other long-term assets/liabilities
|
|
20
|
|
|
(2
|
)
|
||
|
Total cash flows used in operating activities of continuing operations
|
|
(88
|
)
|
|
(14
|
)
|
||
|
Cash flows from investing activities:
|
|
|
|
|
||||
|
Payments for property, plant and equipment
|
|
(7
|
)
|
|
(4
|
)
|
||
|
Proceeds from collections on promissory note
|
|
2
|
|
|
—
|
|
||
|
Net proceeds from sale of assets
|
|
—
|
|
|
3
|
|
||
|
Total cash flows used in investing activities of continuing operations
|
|
(5
|
)
|
|
(1
|
)
|
||
|
Cash flows from financing activities:
|
|
|
|
|
||||
|
Payments of long-term debt
|
|
(22
|
)
|
|
(1
|
)
|
||
|
Proceeds from issuances of stock
|
|
1
|
|
|
2
|
|
||
|
Repurchases of stock and other
|
|
(6
|
)
|
|
(9
|
)
|
||
|
Dividend payments
|
|
(50
|
)
|
|
(23
|
)
|
||
|
Total cash flows used in financing activities of continuing operations
|
|
(77
|
)
|
|
(31
|
)
|
||
|
Decrease in cash and cash equivalents from continuing operations
|
|
(170
|
)
|
|
(46
|
)
|
||
|
Cash flows from discontinued operations:
|
|
|
|
|
||||
|
Cash used in investing activities of discontinued operations
|
|
—
|
|
|
(1
|
)
|
||
|
Decrease in cash and cash equivalents from discontinued operations
|
|
—
|
|
|
(1
|
)
|
||
|
Total decrease in cash and cash equivalents
|
|
(170
|
)
|
|
(47
|
)
|
||
|
Cash and cash equivalents at beginning of period
|
|
376
|
|
|
656
|
|
||
|
Cash and cash equivalents at end of period
|
|
$
|
206
|
|
|
$
|
609
|
|
|
|
|
Three Months Ended
|
||||||
|
|
|
March 31,
2017 |
|
April 1,
2016 |
||||
|
|
|
(in millions, except per share amounts)
|
||||||
|
Net favorable impact to income from continuing operations before taxes
|
|
$
|
22
|
|
|
$
|
8
|
|
|
Impact on diluted EPS from continuing operations attributable to Leidos common stockholders
|
|
$
|
0.09
|
|
|
$
|
0.07
|
|
|
Value of common stock issued to Lockheed Martin stockholders
(1)
|
$
|
2,929
|
|
|
Equity consideration for replacement awards
(2)
|
9
|
|
|
|
Preliminary working capital adjustments
|
56
|
|
|
|
Preliminary purchase price
|
$
|
2,994
|
|
|
Cash
|
$
|
25
|
|
|
Receivables
|
943
|
|
|
|
Inventory, prepaid expenses and other current assets
|
73
|
|
|
|
Property, plant and equipment
|
114
|
|
|
|
Deferred tax assets
|
12
|
|
|
|
Intangible assets
|
1,650
|
|
|
|
Other assets
|
104
|
|
|
|
Accounts payable
|
(286
|
)
|
|
|
Accrued liabilities
|
(446
|
)
|
|
|
Accrued payroll and employee benefits
|
(190
|
)
|
|
|
Long-term debt, current portion
|
(23
|
)
|
|
|
Deferred tax liabilities
|
(556
|
)
|
|
|
Long-term debt, net of current portion
|
(1,780
|
)
|
|
|
Other long-term liabilities
|
(50
|
)
|
|
|
Total identifiable net liabilities assumed
|
(410
|
)
|
|
|
Non-controlling interest
|
(8
|
)
|
|
|
Goodwill
|
3,412
|
|
|
|
Preliminary purchase price
|
$
|
2,994
|
|
|
|
|
Weighted average amortization period
|
|
Fair value
|
||
|
|
|
(in years)
|
|
(in millions)
|
||
|
Programs and contract intangibles
(1)
|
|
10.0
|
|
$
|
1,450
|
|
|
Backlog
|
|
1.4
|
|
200
|
|
|
|
Total
|
|
9.0
|
|
$
|
1,650
|
|
|
|
|
Three Months Ended
|
||||||
|
|
|
March 31,
2017 |
|
April 1,
2016 |
||||
|
|
|
(in millions)
|
||||||
|
Acquisition costs
|
|
$
|
1
|
|
|
$
|
6
|
|
|
Integration costs
|
|
18
|
|
|
3
|
|
||
|
Total acquisition and integration costs
|
|
$
|
19
|
|
|
$
|
9
|
|
|
|
|
Three Months Ended
|
||
|
(unaudited)
|
|
April 1,
2016 |
||
|
|
|
(in millions, except per share amounts)
|
||
|
Revenues
|
|
$
|
2,637
|
|
|
Income from continuing operations
|
|
52
|
|
|
|
Income from continuing operations attributable to Leidos common stockholders
|
|
50
|
|
|
|
Earnings per share:
|
|
|
||
|
Basic
|
|
$
|
0.34
|
|
|
Diluted
|
|
0.33
|
|
|
|
|
|
Three Months Ended
|
||
|
|
|
March 31,
2017 |
||
|
|
|
(in millions)
|
||
|
Severance costs
|
|
$
|
10
|
|
|
Lease termination expenses
|
|
3
|
|
|
|
Restructuring expenses related to the IS&GS Business
|
|
$
|
13
|
|
|
|
|
Severance costs
|
|
Lease termination expenses
|
|
Total
|
||||||
|
|
|
(in millions)
|
||||||||||
|
Balance as of December 30, 2016
|
|
$
|
7
|
|
|
$
|
1
|
|
|
$
|
8
|
|
|
Charges
|
|
10
|
|
|
3
|
|
|
13
|
|
|||
|
Cash payments
|
|
(14
|
)
|
|
(3
|
)
|
|
(17
|
)
|
|||
|
Balance as of March 31, 2017
|
|
$
|
3
|
|
|
$
|
1
|
|
|
$
|
4
|
|
|
|
|
March 31, 2017
|
|
December 30, 2016
|
||||||||||||
|
|
|
Carrying Value
|
|
Fair Value
|
|
Carrying Value
|
|
Fair Value
|
||||||||
|
|
|
(in millions)
|
||||||||||||||
|
Financial assets
|
|
|
|
|
|
|
|
|
||||||||
|
Derivatives
|
|
$
|
31
|
|
|
$
|
31
|
|
|
$
|
29
|
|
|
$
|
29
|
|
|
|
|
Defense Solutions
|
|
Civil
|
|
Health
|
|
Total
|
||||||||
|
|
|
(in millions)
|
||||||||||||||
|
Goodwill at January 1, 2016
|
|
$
|
792
|
|
|
$
|
244
|
|
|
$
|
171
|
|
|
$
|
1,207
|
|
|
Acquisition of the IS&GS Business
|
|
1,162
|
|
|
1,487
|
|
|
766
|
|
|
3,415
|
|
||||
|
Goodwill at December 30, 2016
|
|
1,954
|
|
|
1,731
|
|
|
937
|
|
|
4,622
|
|
||||
|
Adjustment to original purchase price allocation
|
|
(1
|
)
|
|
(1
|
)
|
|
(1
|
)
|
|
(3
|
)
|
||||
|
Goodwill at March 31, 2017
|
|
$
|
1,953
|
|
|
$
|
1,730
|
|
|
$
|
936
|
|
|
$
|
4,619
|
|
|
|
|
March 31, 2017
|
|
December 30, 2016
|
||||||||||||||||||||
|
|
|
Gross carrying value
|
|
Accumulated amortization
|
|
Net carrying value
|
|
Gross carrying value
|
|
Accumulated amortization
|
|
Net carrying value
|
||||||||||||
|
|
|
(in millions)
|
||||||||||||||||||||||
|
Finite-lived intangible assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
Programs and contract intangibles
|
|
$
|
1,450
|
|
|
$
|
(57
|
)
|
|
$
|
1,393
|
|
|
$
|
1,450
|
|
|
$
|
(25
|
)
|
|
$
|
1,425
|
|
|
Backlog
|
|
200
|
|
|
(91
|
)
|
|
109
|
|
|
200
|
|
|
(54
|
)
|
|
146
|
|
||||||
|
Software and technology
|
|
61
|
|
|
(48
|
)
|
|
13
|
|
|
61
|
|
|
(48
|
)
|
|
13
|
|
||||||
|
Customer relationships
|
|
6
|
|
|
(5
|
)
|
|
1
|
|
|
6
|
|
|
(5
|
)
|
|
1
|
|
||||||
|
Total finite-lived intangible assets
|
|
1,717
|
|
|
(201
|
)
|
|
1,516
|
|
|
1,717
|
|
|
(132
|
)
|
|
1,585
|
|
||||||
|
Indefinite-lived intangible assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
|
Trade names
|
|
4
|
|
|
—
|
|
|
4
|
|
|
4
|
|
|
—
|
|
|
4
|
|
||||||
|
Total intangible assets
|
|
$
|
1,721
|
|
|
$
|
(201
|
)
|
|
$
|
1,520
|
|
|
$
|
1,721
|
|
|
$
|
(132
|
)
|
|
$
|
1,589
|
|
|
Fiscal Year Ending
|
|
|
||
|
|
|
(in millions)
|
||
|
2017 (remainder of year)
|
|
$
|
208
|
|
|
2018
|
|
213
|
|
|
|
2019
|
|
188
|
|
|
|
2020
|
|
165
|
|
|
|
2021
|
|
139
|
|
|
|
2022 and thereafter
|
|
603
|
|
|
|
|
|
$
|
1,516
|
|
|
|
|
March 31,
2017 |
|
December 30,
2016 |
||||
|
|
|
(in millions)
|
||||||
|
Computers and other equipment
|
|
$
|
193
|
|
|
$
|
172
|
|
|
Leasehold improvements
|
|
165
|
|
|
161
|
|
||
|
Buildings and improvements
|
|
62
|
|
|
104
|
|
||
|
Office furniture and fixtures
|
|
41
|
|
|
35
|
|
||
|
Land
|
|
52
|
|
|
57
|
|
||
|
Construction in progress
|
|
14
|
|
|
12
|
|
||
|
|
|
527
|
|
|
541
|
|
||
|
Less: accumulated depreciation and amortization
|
|
(289
|
)
|
|
(282
|
)
|
||
|
|
|
$
|
238
|
|
|
$
|
259
|
|
|
|
|
Balance sheet line item
|
|
March 31,
2017 |
|
December 30,
2016 |
||||
|
|
|
|
|
(in millions)
|
||||||
|
Fair value interest rate swaps
|
|
Other assets
|
|
$
|
3
|
|
|
$
|
3
|
|
|
Cash flow interest rate swaps
|
|
Other assets
|
|
28
|
|
|
26
|
|
||
|
|
|
Three Months Ended
|
||
|
|
|
March 31,
2017 |
||
|
|
|
(in millions)
|
||
|
Effective portion recognized in other comprehensive income
|
|
$
|
1
|
|
|
Effective portion reclassified from accumulated other comprehensive income (loss) to earnings
|
|
1
|
|
|
|
|
|
Stated interest rate
|
|
Effective interest rate
|
|
March 31, 2017
(1)
|
|
December 30, 2016
(1)
|
||||
|
|
|
|
|
|
|
(in millions)
|
||||||
|
Senior secured notes:
|
|
|
|
|
|
|
|
|
||||
|
$450 million notes, due December 2020
|
|
4.45%
|
|
4.53%
|
|
$
|
451
|
|
|
$
|
451
|
|
|
$300 million notes, due December 2040
|
|
5.95%
|
|
6.03%
|
|
216
|
|
|
216
|
|
||
|
Senior secured term loans:
|
|
|
|
|
|
|
|
|
||||
|
$400 million Term Loan A, due August 2019
|
|
2.81%
|
|
3.73%
|
|
118
|
|
|
123
|
|
||
|
$690 million Term Loan A, due August 2021
|
|
2.81%
|
|
3.37%
|
|
668
|
|
|
676
|
|
||
|
$310 million Term Loan A, due August 2021
|
|
2.81%
|
|
3.35%
|
|
301
|
|
|
304
|
|
||
|
$1,131 million Term Loan B, due August 2023
|
|
3.06%
|
|
3.42%
|
|
1,107
|
|
|
1,110
|
|
||
|
Senior unsecured notes:
|
|
|
|
|
|
|
|
|
||||
|
$250 million notes, due July 2032
|
|
7.13%
|
|
7.43%
|
|
246
|
|
|
246
|
|
||
|
$300 million notes, due July 2033
|
|
5.50%
|
|
5.88%
|
|
158
|
|
|
158
|
|
||
|
Capital leases due on various dates through fiscal 2020
|
|
0%-5.94%
|
|
Various
|
|
7
|
|
|
3
|
|
||
|
Total notes payable and long-term debt
|
|
|
|
|
|
3,272
|
|
|
3,287
|
|
||
|
Less: current portion
|
|
|
|
|
|
84
|
|
|
62
|
|
||
|
Total notes payable and long-term debt, net of current portion
|
|
|
|
|
|
$
|
3,188
|
|
|
$
|
3,225
|
|
|
(1)
|
The carrying amounts of the senior secured term loans and notes and unsecured notes as of March 31, 2017, and December 30, 2016, include the remaining principal outstanding of
$3,315 million
and
$3,336 million
, respectively, plus
$3 million
for both periods related to the fair value of the interest rate swaps (see "Note 9–Derivative Instruments"), less unamortized debt discounts of
$43 million
and
$46 million
, respectively, less deferred debt issuance costs of
$10 million
and
$9 million
, respectively.
|
|
|
|
Foreign currency translation adjustments
|
|
Unrecognized (loss) gain on derivative instruments
|
|
Pension liability adjustments
|
|
Total accumulated other comprehensive income (loss)
|
||||||||
|
|
|
(in millions)
|
||||||||||||||
|
Balance at January 1, 2016
|
|
$
|
—
|
|
|
$
|
(4
|
)
|
|
$
|
(4
|
)
|
|
$
|
(8
|
)
|
|
Other comprehensive (loss) income
|
|
(8
|
)
|
|
26
|
|
|
1
|
|
|
19
|
|
||||
|
Taxes
|
|
1
|
|
|
(10
|
)
|
|
2
|
|
|
(7
|
)
|
||||
|
Reclassification from accumulated other comprehensive income (loss)
|
|
—
|
|
|
(2
|
)
|
|
(6
|
)
|
|
(8
|
)
|
||||
|
Balance at December 30, 2016
|
|
(7
|
)
|
|
10
|
|
|
(7
|
)
|
|
(4
|
)
|
||||
|
Other comprehensive income
|
|
13
|
|
|
2
|
|
|
—
|
|
|
15
|
|
||||
|
Taxes
|
|
(2
|
)
|
|
—
|
|
|
—
|
|
|
(2
|
)
|
||||
|
Reclassification from accumulated other comprehensive income (loss)
|
|
—
|
|
|
(1
|
)
|
|
—
|
|
|
(1
|
)
|
||||
|
Balance at March 31, 2017
|
|
$
|
4
|
|
|
$
|
11
|
|
|
$
|
(7
|
)
|
|
$
|
8
|
|
|
|
|
Three Months Ended
|
||||
|
|
|
March 31,
2017 |
|
April 1,
2016 |
||
|
|
|
(in millions)
|
||||
|
Basic weighted average number of shares outstanding
|
|
150
|
|
|
72
|
|
|
Dilutive common share equivalents—stock options and other stock awards
|
|
3
|
|
|
2
|
|
|
Diluted weighted average number of shares outstanding
|
|
153
|
|
|
74
|
|
|
|
|
Three Months Ended
|
||||||
|
|
|
March 31,
2017 |
|
April 1,
2016 |
||||
|
|
|
(in millions)
|
||||||
|
Supplementary cash flow information:
|
|
|
|
|
||||
|
Cash paid for interest
|
|
$
|
32
|
|
|
$
|
13
|
|
|
Cash paid for income taxes, net of refunds
|
|
1
|
|
|
17
|
|
||
|
Non-cash financing activity:
|
|
|
|
|
||||
|
Capital lease obligation
|
|
6
|
|
|
—
|
|
||
|
•
|
Defense Solutions – delivers cutting edge technology and services to the DoD, military services, the U.S. Intelligence Community, DHS, agencies of U.S. allies abroad and other federal and civilian customers. The Company's Defense Solutions business is focused on cybersecurity, data analytics, IT modernization and software development, as well as technology to support intelligence, surveillance and reconnaissance services.
|
|
•
|
Civil – provides services and solutions to civil agencies of the U.S. Government and commercial customers. The Company's Civil business is focused on software development, operations and sustainment, enterprise IT modernization, systems engineering and cyber services.
|
|
•
|
Health – provides services and solutions to the Defense Health Agency, Veterans Administration, HHS, other civil health agencies of the U.S. Government and commercial healthcare providers. The Company's Health business is focused on enterprise IT modernization, software development, data analytics, electronic health record implementation, mission critical operations and sustainment, life sciences and public health.
|
|
•
|
Corporate – includes the operations of various corporate activities and certain expense items that are not reimbursed by our U.S. Government customers.
|
|
|
|
Three Months Ended
|
||||||
|
|
|
March 31,
2017 |
|
April 1,
2016 |
||||
|
|
|
(in millions)
|
||||||
|
Revenues:
|
|
|
|
|
||||
|
Defense Solutions
|
|
$
|
1,294
|
|
|
$
|
780
|
|
|
Civil
|
|
842
|
|
|
361
|
|
||
|
Health
|
|
443
|
|
|
171
|
|
||
|
Corporate
|
|
1
|
|
|
—
|
|
||
|
Total revenues
|
|
$
|
2,580
|
|
|
$
|
1,312
|
|
|
|
|
|
|
|
||||
|
Operating income (loss):
|
|
|
|
|
||||
|
Defense Solutions
|
|
$
|
79
|
|
|
$
|
71
|
|
|
Civil
|
|
54
|
|
|
22
|
|
||
|
Health
|
|
47
|
|
|
16
|
|
||
|
Corporate
|
|
(39
|
)
|
|
(20
|
)
|
||
|
Total operating income
|
|
$
|
141
|
|
|
$
|
89
|
|
|
|
|
Three Months Ended
|
|||||||||||||
|
|
|
March 31,
2017 |
|
April 1,
2016 |
|
Dollar change
|
|
Percent change
|
|||||||
|
|
|
(dollars in millions)
|
|||||||||||||
|
Revenues
|
|
$
|
2,580
|
|
|
$
|
1,312
|
|
|
$
|
1,268
|
|
|
96.6
|
%
|
|
|
|
|
|
|
|
|
|
|
|||||||
|
Operating income
|
|
141
|
|
|
89
|
|
|
52
|
|
|
58.4
|
%
|
|||
|
Non-operating expense, net
|
|
(33
|
)
|
|
(11
|
)
|
|
(22
|
)
|
|
200.0
|
%
|
|||
|
Income from continuing operations before income taxes
|
|
108
|
|
|
78
|
|
|
30
|
|
|
38.5
|
%
|
|||
|
Income tax expense
|
|
(34
|
)
|
|
(25
|
)
|
|
(9
|
)
|
|
36.0
|
%
|
|||
|
Net income
|
|
74
|
|
|
53
|
|
|
21
|
|
|
39.6
|
%
|
|||
|
Less: net income attributable to non-controlling interest, net of taxes
|
|
2
|
|
|
—
|
|
|
2
|
|
|
NM
|
|
|||
|
Net income attributable to Leidos common stockholders
|
|
$
|
72
|
|
|
$
|
53
|
|
|
$
|
19
|
|
|
35.8
|
%
|
|
Operating margin
|
|
5.5
|
%
|
|
6.8
|
%
|
|
|
|
|
|||||
|
|
|
Three Months Ended
|
|||||||||||||
|
Defense Solutions
|
|
March 31,
2017 |
|
April 1,
2016 |
|
Dollar change
|
|
Percent change
|
|||||||
|
|
|
(dollars in millions)
|
|||||||||||||
|
Revenues
|
|
$
|
1,294
|
|
|
$
|
780
|
|
|
$
|
514
|
|
|
65.9
|
%
|
|
Operating income
|
|
79
|
|
|
71
|
|
|
8
|
|
|
11.3
|
%
|
|||
|
Operating income margin
|
|
6.1
|
%
|
|
9.1
|
%
|
|
|
|
|
|||||
|
|
|
Three Months Ended
|
|||||||||||||
|
Civil
|
|
March 31,
2017 |
|
April 1,
2016 |
|
Dollar change
|
|
Percent change
|
|||||||
|
|
|
(dollars in millions)
|
|||||||||||||
|
Revenues
|
|
$
|
842
|
|
|
$
|
361
|
|
|
$
|
481
|
|
|
133.2
|
%
|
|
Operating income
|
|
54
|
|
|
22
|
|
|
32
|
|
|
145.5
|
%
|
|||
|
Operating income margin
|
|
6.4
|
%
|
|
6.1
|
%
|
|
|
|
|
|||||
|
|
|
Three Months Ended
|
|||||||||||||
|
Health
|
|
March 31,
2017 |
|
April 1,
2016 |
|
Dollar change
|
|
Percent change
|
|||||||
|
|
|
(dollars in millions)
|
|||||||||||||
|
Revenues
|
|
$
|
443
|
|
|
$
|
171
|
|
|
$
|
272
|
|
|
159.1
|
%
|
|
Operating income
|
|
47
|
|
|
16
|
|
|
31
|
|
|
193.8
|
%
|
|||
|
Operating income margin
|
|
10.6
|
%
|
|
9.4
|
%
|
|
|
|
|
|||||
|
|
|
Three Months Ended
|
|||||||||||||
|
Corporate
|
|
March 31,
2017 |
|
April 1,
2016 |
|
Dollar change
|
|
Percent change
|
|||||||
|
|
|
(dollars in millions)
|
|||||||||||||
|
Revenues
|
|
$
|
1
|
|
|
$
|
—
|
|
|
$
|
1
|
|
|
NM
|
|
|
Operating loss
|
|
(39
|
)
|
|
(20
|
)
|
|
(19
|
)
|
|
95.0
|
%
|
|||
|
NM - Not meaningful
|
|
|
|
|
|
|
|
|
|||||||
|
|
|
March 31,
2017 |
|
December 30,
2016 |
||||
|
|
|
(in millions)
|
||||||
|
Defense Solutions:
|
|
|
|
|
||||
|
Funded backlog
|
|
$
|
2,572
|
|
|
$
|
3,171
|
|
|
Negotiated unfunded backlog
|
|
5,005
|
|
|
4,936
|
|
||
|
Total Defense Solutions backlog
|
|
$
|
7,577
|
|
|
$
|
8,107
|
|
|
Civil:
|
|
|
|
|
||||
|
Funded backlog
|
|
$
|
1,596
|
|
|
$
|
1,950
|
|
|
Negotiated unfunded backlog
|
|
5,466
|
|
|
5,250
|
|
||
|
Total Civil backlog
|
|
$
|
7,062
|
|
|
$
|
7,200
|
|
|
Health:
|
|
|
|
|
||||
|
Funded backlog
|
|
$
|
684
|
|
|
$
|
854
|
|
|
Negotiated unfunded backlog
|
|
1,566
|
|
|
1,575
|
|
||
|
Total Health backlog
|
|
$
|
2,250
|
|
|
$
|
2,429
|
|
|
Total:
|
|
|
|
|
||||
|
Funded backlog
|
|
$
|
4,852
|
|
|
$
|
5,975
|
|
|
Negotiated unfunded backlog
|
|
12,037
|
|
|
11,761
|
|
||
|
Total backlog
|
|
$
|
16,889
|
|
|
$
|
17,736
|
|
|
|
|
Three Months Ended
|
||||||
|
|
|
March 31,
2017 |
|
April 1,
2016 |
||||
|
|
|
(in millions)
|
||||||
|
Cash used in operating activities of continuing operations
|
|
$
|
(88
|
)
|
|
$
|
(14
|
)
|
|
Cash used in investing activities of continuing operations
|
|
(5
|
)
|
|
(1
|
)
|
||
|
Cash used in financing activities of continuing operations
|
|
(77
|
)
|
|
(31
|
)
|
||
|
Decrease in cash and cash equivalents from continuing operations
|
|
(170
|
)
|
|
(46
|
)
|
||
|
Decrease in cash and cash equivalents from discontinued operations
|
|
—
|
|
|
(1
|
)
|
||
|
Total decrease in cash and cash equivalents
|
|
$
|
(170
|
)
|
|
$
|
(47
|
)
|
|
(a)
|
None
|
|
(b)
|
None
|
|
(c)
|
Purchases of Equity Securities by the Company
|
|
Period
|
|
Total Number of Shares
(or Units) Purchased (1) |
|
Average Price
Paid per Share (or Unit) |
|
Total Number of Shares
(or Units) Purchased as Part of Publicly Announced Repurchase Plans or Programs |
|
Maximum Number of Shares (or Units) that May Yet Be
Purchased Under the Plans or Programs |
|||||
|
December 31, 2016
|
|
—
|
|
|
$
|
—
|
|
|
—
|
|
|
5,718,172
|
|
|
January 1, 2017 - January 31, 2017
|
|
20,029
|
|
|
50.77
|
|
|
—
|
|
|
5,718,172
|
|
|
|
February 1, 2017 - February 28, 2017
|
|
6,112
|
|
|
48.76
|
|
|
—
|
|
|
5,718,172
|
|
|
|
March 1, 2017 - March 31, 2017
|
|
10,775
|
|
|
53.21
|
|
|
—
|
|
|
5,718,172
|
|
|
|
Total
|
|
36,916
|
|
|
51.15
|
|
|
—
|
|
|
|
||
|
(1)
|
The total number of shares purchased includes: (i) shares surrendered to satisfy statutory tax withholdings obligations related to vesting of restricted stock units; and (ii) shares purchased upon surrender by stockholders of previously owned shares in payment of the exercise price of non-qualified stock options and/or to satisfy statutory tax withholdings obligations.
|
|
Exhibit
Number |
|
Description of Exhibit
|
|
10.1
|
|
Notice of Separation and Release of Claims dated January 19, 2017. Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed with the SEC on January 20, 2017.
|
|
|
|
|
|
10.2
|
|
First Amendment, dated February 16, 2017, to the Credit Agreement dated as of August 16, 2016, by and among Leidos Innovations (f/k/a Abacus Innovations Corporation), as borrower, Leidos Holdings, Inc., Citibank, N.A., as administrative agent and the other lending institutions party to the amendment. Incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed with the SEC on February 21, 2017.
|
|
|
|
|
|
10.3
|
|
Form of Restricted Stock Unit Award Agreement of Leidos Holdings, Inc.'s 2006 Equity Incentive Plan.
|
|
|
|
|
|
10.4
|
|
Form of Nonstatutory Stock Option Agreement of Leidos Holdings, Inc.'s 2006 Equity Incentive Plan.
|
|
|
|
|
|
10.5
|
|
Form of Performance Share Award Agreement of Leidos Holdings, Inc.'s 2006 Equity Incentive Plan.
|
|
|
|
|
|
31.1
|
|
Certification of Chairman and Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
|
|
|
|
31.2
|
|
Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
|
|
|
|
|
|
32.1
|
|
Certification of Chairman and Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
|
|
|
|
|
32.2
|
|
Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|
|
|
|
|
|
101
|
|
Interactive Data File.
|
|
Leidos Holdings, Inc.
|
|
|
|
/s/ James C. Reagan
|
|
James C. Reagan
Executive Vice President and Chief Financial Officer and
as a duly authorized officer
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|